Streetbeat News

ZVSA

ZyVersa Therapeutics, Inc.

https://www.zyversa.com

Industry

Biotechnology

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Open

0.59

Mkt cap

1.5M

Volume

6.1K

High

0.61

P/E Ratio

-0.07

52-wk high

8.05

Low

0.58

Div yield

N/A

52-wk low

0.58

ZyVersa Therapeutics has published data showing that their NLRP3 Inhibition can reduce neuroinflammation and amyloid beta deposition in Alzheimer's disease mouse models, potentially slowing disease progression.

Portfolio Pulse from

March 12, 2025 | 12:15 pm

ZyVersa Therapeutics, Inc. has announced a $2.0 million private placement with a U.S. institutional investor, involving the sale of over 2 million shares and warrants at $0.95 per share.

Portfolio Pulse from

March 06, 2025 | 1:15 pm

ZyVersa Therapeutics has presented data showing that their NLRP3 inflammasome inhibitor can reduce inflammation, improve heart function, and restore glucose homeostasis and insulin sensitivity in an obese animal model of heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes.

Portfolio Pulse from

March 05, 2025 | 1:00 pm

ZyVersa Therapeutics has released its Q3 2024 financial results and provided a business update. Key highlights include the upcoming Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients and the formation of a new Scientific Advisory Board to support the development of IC 100 for obesity-related metabolic complications.

Portfolio Pulse from

November 14, 2024 | 1:30 pm

ZyVersa Therapeutics, iRhythm Technologies, and 3M shares are trading higher due to positive developments. ZyVersa published promising research, iRhythm received FDA clearance, and 3M reported strong earnings and raised guidance.